GlassScriptPhysician profile
Thomas D Verla
NPI 1376890582
$631.83
in general payments reported to CMS, 2019-2025
15 companies · $128 in 2025
The $128 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $57.10 · 2020: $34.25 · 2021: $85.46 · 2022: $85.84 · 2023: $85.49 · 2024: $156 · 2025: $128.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $369.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $369.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $190.88 | 2021-2025 | Cygnus Dual, Apligraf, Affinity |
| Paratek Pharmaceuticals, INC. | $104.13 | 2022-2025 | Nuzyra |
| Bioventus LLC | $55.78 | 2022-2025 | Exogen Ultrasound Bone Healing System |
| Vaporox, INC. | $53.15 | 2023 | Vht-200 Wound Treatment System |
| Melinta Therapeutics, LLC | $41.57 | 2019 | |
| Peerless Surgical INC. | $33.58 | 2024 | |
| Zimmer Biomet Holdings, INC. | $25.91 | 2020 | |
| Smith+Nephew, INC. | $21.71 | 2024 | Grafix Pl |
| Solventum Corporation | $19.87 | 2024 | Promogran Prisma, Snap, Activ.A.C. |
| Reprise Biomedical, INC. | $17.70 | 2024 | Miro3d |
| Averitas Pharma INC. | $15.71 | 2024 | Qutenza |
| Paragon 28, INC. | $15.53 | 2019 | |
| Convatec INC. | $14.33 | 2024 | |
| Orthofix Medical, INC. | $13.64 | 2024 | Accelstim, Physio-Stim |
| Kerecis Limited | $8.34 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Verla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.